The headline reads as positive (72% confidence from the FinBERT financial-language model), so the stock went through the full analysis. The rest of the picture is mixed, so the headline alone is not enough for a clear call.
Stocks › BAX
Baxter International Inc (BAX) stock analysis
SKIP 10% confidence · analysed Oct 29, 2026
On Oct 29, 2026, our model rated Baxter International Inc (BAX) SKIP with 10% confidence at a price of $23.73. That means the signals cancel out; the model sees no clear edge either way.
Analysed price$23.73
Technical picture
The 14-day RSI is 46, close to the neutral 50 line, so momentum is balanced.
MACD is below its signal line, so short-term momentum is pointing down.
The price has slipped below its 50-day moving average but is still above the 200-day: a pullback inside a longer-term uptrend.
Volume is 1.8x its 20-day average, so the latest move has real participation behind it.
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $29.99 and the swing low is $15.72; traders often treat these as resistance and support.
Fundamentals
The PEG ratio is 36.68, which looks expensive relative to its growth.
The company reports a profit margin of -9.3% and revenue growth of +5.3%.
In its latest quarter it earned $0.58 per share, which beat the $0.52 analysts expected, with revenue +5.3% year over year.
Wall Street's average rating is 2.9 on a 1 (strong buy) to 5 (sell) scale, roughly a "hold", with an average price target of $27.92.
Research notes
Baxter’s bull case is broad-based recovery: Q3 2026 sales rose 5% to $2.98 billion, adjusted EPS beat estimates at $0.58, and management raised full-year adjusted EPS guidance to $2.05–$2.15. The bear case is that EPS still fell from $0.69 a year earlier, while investors face 2027 margin pressure from inflation, potential tariffs, reduced transition-support revenue, and the cephalosporin production exit. The major catalyst today was the Q3 earnings release and raised outlook, but the stock fell roughly 4–5% as investors focused on those forward margin concerns and an FDA warning letter involving Baxter’s Round Lake facility.
The model's one-paragraph read
No clear edge (SKIP) — composite score -0.10 (SKIP). Technicals: RSI 45.59, MACD bearish, price below SMA50. Fundamentals: PEG 36.68, margin -9.3%, revenue growth 5.3%. Financial results: YoY revenue +5.3%, last EPS surprise +11.5%. Smart Money Concepts: ranging / no clear structure. FinGPT news read: positive. Internet research: Baxter’s **bull case** is broad-based recovery: Q3 2026 sales rose 5% to $2.98 billion, adjusted EPS beat estimates at $0.58, and management raised full-year adjusted EPS guidance to $2.05–$2.15. The **bear case** is that EPS still fell from $0.69 a year earlier, while investors face 2027 margin pressure from inflation, potential tariffs, reduced transition-support revenue, and the cephalosporin production exit. The major catalyst today was the Q3 earnings release and raised outlook, but the stock fell roughly 4–5% as investors focused on those forward margin concerns and an FDA warning letter involving Baxter’s Round Lake facility. Reference price $23.75; no trade levels (SKIP).
Past ratings for BAX
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 29, 2026 | SKIP | 10% | $23.73 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on BAX
Oct 29, 2026 · Baxter Beats And Raises Again As Turnaround Firms, But Margin Pressure, A New FDA Warning Letter And 2027 Headwinds Temper The Setup
- Oct 29, 2026: Baxter International Inc. stock underperforms Thursday when compared to competitors (MarketWatch)
- Oct 29, 2026: Baxter Beats And Raises Again As Turnaround Firms, But Margin Pressure, A New FDA Warning Letter And 2027 Headwinds Temper The Setup (Earnings Whispers)
- Oct 29, 2026: Baxter: Q3 Earnings Snapshot (Associated Press)
- Oct 29, 2026: Baxter Reports Third-Quarter 2026 Results (Business Wire)
Frequently asked questions
Is BAX a buy right now?
As of Oct 29, 2026, our automated model rates Baxter International Inc (BAX) SKIP with 10% confidence: the signals cancel out; the model sees no clear edge either way. This is a model output for education, not personal investment advice.
What does a SKIP rating mean?
A SKIP rating means the signals cancel out; the model sees no clear edge either way.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.